Aug 31 (Reuters) - UCB SA UCB.BR :
* PHASE 3 DATA ON VIMPAT® (LACOSAMIDE) IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURES PUBLISHED IN JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY
* LACOSAMIDE WAS GENERALLY TOLERATED BY PATIENTS ENROLLED IN STUDY
* STUDY MET PRIMARY AND SECONDARY ENDPOINTS OF SIGNIFICANTLY LOWERING RISK OF DEVELOPING A SECOND PRIMARY GENERALIZED TONIC-CLONIC SEIZURE (PGTCS) DURING A 24-WEEK TREATMENT AND A SIGNIFICANTLY HIGHER RATE OF FREEDOM FROM PGTCS DURING TREATMENT PERIOD COMPARED WITH PLACEBO
* VIMPAT® IS CURRENTLY NOT APPROVED FOR PGTCS IN ANY COUNTRY IN WORLD
* REGULATORY REVIEWS, BASED, IN PART, ON THESE DATA, ARE CURRENTLY UNDERWAY IN THE U.S., EU, JAPAN, AND AUSTRALIA